IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market

Analysis by Drug Class (TNF Inhibitors, Amino Salicylates, Integrin Antagonists, Corticosteroids, and Others); by Disease Indication (Ulcerative Colitis and Crohn’s Disease); and by Distribution Channel (Hospital, Retail, and Online Pharmacies) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2033

Buy Now
Report ID: 4685 | Published On: Feb 03, 2023
Request Free Sample Copy

Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size, Forecast, and Trend Highlights Over 2023 - 2033

The global IBD (ulcerative colitis and Crohn's disease) treatment market is estimated to garner a revenue of USD 36 Billion by the end of 2033 by growing at a CAGR of ~8% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of USD 20 Billion in the year 2022. The growth of the market can be attributed to the increasing number of inflammatory bowel diseases, including fecal incontinence, diarrhea, and constipation, across the world. As per the World Health Organization, the second most common cause of death in children under the age of five is diarrhea. Around 525 000 children under five dies from diarrhea each year. Every year, there are around 1.7 billion cases of pediatric diarrheal illness worldwide.

IBD-(Ulcerative-Colitis-and-Crohn's-Disease)-Treatment-Market-overviewGet more information on this report:Download Sample PDF

Global IBD (ulcerative colitis and Crohn's disease) treatment market trends such as, higher number of people with inflammatory intestine disease backed by the approval of new biologic drugs for IBD. Hence, the development of novel drugs is anticipated to hike the market growth over the forecast period. It was found that in contrast to the typical review process, which takes 10 months, FDA intends to act on an application within 6 months. Additionally, the rise in demand for IBD treatment in developing nations is also one of the major factors that are predicted to drive the global market for IBD (ulcerative colitis and Crohn's disease) treatments over the forecast period. Drugs that would considerably improve the treatment, diagnosis, or prevention of critical illnesses are given a priority review classification, which focuses attention and resources on their evaluation.

Get more information on this report: Request Sample PDF

Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2022)

~ USD 20 Billion

Forecast Year Market Size (2033)

~ USD 36 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market: Growth Drivers and Challenges

Growth Drivers

  • Growing Prevalence of Crohn’s Disease– As many as 780,000 people in the United States are affected by Crohn's disease, making it a widespread ailment. The disease is most prevalent in people between the ages of 15 and 35, with 25% of cases being identified by age 20. Crohn's disease is a kind of inflammatory bowel disease (IBD). Crohn’s disease causes swelling of the tissues (inflammation) in the digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. This disease may lead the patients to the potentially fatal and serious complications. Hence, the increasing cases of Crohn’s disease are estimated to drive the market’s growth.

  • Increasing Investment in Research and Development – For instance, investment in medical and health research and development (R&D) in the United States (U.S.) increased by 11% to around USD245 billion in 2020 from 2019.

  • Growing Spending on Rare Disease – It was observed that approximately USD 997 billion is spent on the prevention, diagnosis, treatment, and awareness of rare diseases, of which USD 449 billion goes directly toward medical expenses and around USD 437 billion accounts for indirect medical costs across the globe.

  • Increasing Cases of Fecal Incontinence – It was found that fecal incontinence affects between 18 to 33 patients out of every 100 hospitalized patients and 50 to 70 patients out of every 100 nursing care residents globally, respectively.


  • High Treatment Cost - IBD (ulcerative colitis and Crohn's disease) treatment becomes expensive since ulcerative colitis and Crohn's disease are chronic diseases that requires treatment for a prolonged time. The treatment includes surgery, medicines, bowl rest, and others since no single treatment can cure patients with these diseases. The average cost of Crohn’s disease treatment in the first year of its diagnosis is projected to be around 25,000 U.S. dollars.
  • Lack of Reimbursement Facility for the Treatment of IBD
  • Lack of Awareness Among People Regarding Inflammatory Bowel Disease (IBD)

Market Segmentation

The global IBD (ulcerative colitis and Crohn's disease) treatment market is segmented and analyzed for demand and supply by disease indication into ulcerative colitis and Crohn’s disease. Out of these types of segments, the crohn’s disease segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the increasing instances of crohn’s diseases compared to ulcerative colitis worldwide, backed by the launch of several healthcare program for early diagnosis and treatment of the disease. For instance, it was noticed that nearly 10 out of 100,000 people across the globe are diagnosed with crohn’s disease every year which sums up to approximate 30,000 new cases of the disease annually.

The global IBD (ulcerative colitis and Crohn's disease) treatment market is also segmented and analyzed for demand and supply by distribution channel into hospital, retail, and online pharmacies. Amongst these segments, the hospital segment is expected to garner a significant share. The growth of the segment can be ascribed to the rising patient flow in the hospitals and increasing spending on healthcare across the globe as a result of doctors' increasing caution and suggestions of tests for the parents. As per the health expenditure report, global health spending has increased overall during the previous 20 years, doubling in real terms, reaching USD 8.5 trillion in 2019 and 9.8% of GDP (up from 8.5% in 2000).

Our in-depth analysis of the global IBD (ulcerative colitis and Crohn's disease) treatment market includes the following segments:

                       By Drug Class

  • TNF Inhibitors
  • Amino Salicylates
  • Integrin Antagonists
  • Corticosteroids
  • Others

                      By Disease Indication

  • Ulcerative Colitis
  • Crohn’s Disease


                     By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Regional Synopsis

The North America IBD (ulcerative colitis and Crohn's disease) treatment market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033. The growth of the market can be attributed majorly to the U.S. and Canada's high prevalence and rising incidence of ulcerative colitis and Crohn's disease, as well as their developed healthcare systems and high risk of lifestyle-related variables. It was found during research that IBD, which includes Crohn's disease and ulcerative colitis, has been identified in an estimated 3.1 million individuals (1%) in the United States, out of which, around 1 million of them were males and remaining was stated to be female. The prevalence of IBD can differ based on the several factors, such as, age, race, sociodemographic characteristics, education, and economic conditions. A report published by Centers for Disease Control and Prevention stated that the instances of IBD rise from 2001 to 2018 among all ethnicity groups, especially in non-Hispanic Black adults in the region. Furthermore, growing awareness of inflammatory bowel disease (IBD) in the region, supported by educational advancement and growth in the number of government initiatives are estimated to enlarge the IBD (ulcerative colitis and Crohn's disease) treatment market size in North America by triggering the prevalence of early diagnosis. For instance, approximately 25 million Medicare fee-for-service beneficiaries aged above 65 went through the diagnosis procedure of Crohn’s disease or ulcerative colitis in the region in 2018.


Get more information on this report: Request Sample PDF

Top Featured Companies Dominating the Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market

    • The Bristol-Myers Squibb Company
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Bausch Health Companies Inc.
    • AbbVie Inc.
    • Novartis AG
    • UCB Biopharma SRL
    • Biogen Inc.
    • Pfizer, Inc.
    • Janssen Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited
    • Celltrion Healthcare Co., Ltd.

In The News

  • April 2022: IBSRELA the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, has been made available by the biopharmaceutical company Ardelyx. The first Ardelyx product to receive approval from the US Food and Drug Administration is IBSRELA.
  • March 2022: Indegene a provider of technology-driven healthcare solutions, & meta Me Health, a maker of Regulora and a Prescription Digital Therapeutics (PDT) business, teamed up to offer Regulora as a remedy for irritable bowel syndrome-related stomach pain (IBS).

Global Economic Impact

Request Insights
Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the IBD treatment market?

Ans: Growing prevalence of Crohn’s disease and growing spending on rare disease are the major factors driving the market growth.

2) What would be the CAGR of IBD treatment market over the forecast period?

Ans: The market is anticipated to attain a CAGR of ~8% over the forecast period, i.e., 2023 – 2033.

3) What are the challenges affecting the IBD treatment market growth?

Ans: Lack of awareness among people regarding inflammatory bowel disease (IBD) are estimated to be the growth hindering factors for the market expansion.

4) Which region will provide more business opportunities for growth of IBD treatment market in future?

Ans: The market in the North America region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

5) Who are the major players dominating the IBD treatment market?

Ans: The major players in the market are Bausch Health Companies Inc., AbbVie Inc., Novartis AG, UCB Biopharma SRL, Biogen Inc., Pfizer, Inc., Janssen Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and others.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the IBD (ulcerative colitis and Crohn's disease) treatment market?

Ans: The market is segmented by drug class, disease indication, distribution channel, and by region.

8) Which segment captures the largest market size in the distribution channel segment in the IBD (ulcerative colitis and Crohn's disease) treatment market?

Ans: The hospital pharmacies segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

Request Research Report Sample